Controversies in the management of hepatitis C virus infection after liver transplantation

Liver Transplantation

Volumn 9, Issue 11, 2003, Pages 1129-1144

  Shiffman, Mitchell L ^a   Vargas, Hugo E ^b   Everson, Gregory T ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b MAYO CLINIC HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; INTERLEUKIN RECEPTOR; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA2A; POLYETHYLENE GLYCOL INTERFERON ALFA 2A; POLYETHYLENE GLYCOL-INTERFERON ALFA-2A; PROCOLLAGEN; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIRUS RNA;

ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; ARTHRALGIA; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CHRONIC DISEASE; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG COMBINATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENOTYPE; GRAFT FAILURE; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LIVER; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LIVING DONOR; MONOTHERAPY; MYALGIA; NEUTROPENIA; PHYSIOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; VIROLOGY; VIRUS REPLICATION;

EID: 0142169629     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50261     Document Type: Review

References (143)

1. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant 2001;1:197-203.
2. Rakela J, Vargas HE. Hepatitis C: Magnitude of the problem. Liver Transpl 2002;8(suppl 1):S3-6.
3. Araya V, Rakela J, Wright T. Hepatitis C after orthotopic liver transplantation. Gastroenterology 1997;112:575-582.
4. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression after liver transplantation: Increase in recent years. J Hepatol 2000;32:673-684.
5. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection after transplantation: Relationship with rejection episodes. Hepatology 1999;29: 250-256.
6. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334: 815-820.
7. Papatheodoridis GV, Davies S, Dhillon AP, Teixeira R, Goulis J, Davidson B, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001; 72:412-418.
8. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: Persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000;6:44-53.
9. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, et al. Severe recurrent cholestatic hepatitis C after orthotopic liver transplantation. Hepatology 1996;23:971-976.
10. Dickson RC, Caldwell SH, Ishitani MB, Lau JY, Driscoll CJ, Stevenson WC, et al. Clinical and histologic patterns of early graft failure because of recurrent hepatitis C in four patients after liver transplantation. Transplantation 1996;61:701-705.
11. Taga SA, Washington MK, Terrault N, Wright TL, Somberg KA, Ferrell LD. Cholestatic hepatitis C in liver allografts. Liver Transpl Surg 1998;4:304-310.
12. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
13. McHutchinson, JG, Gordan S, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
14. Ahmed A, Keeffe EB. Hepatitis C virus and liver transplantation. Clin Liver Dis 2001;5:1073-1090.
15. Gane E. Treatment of recurrent hepatitis C. Liver Transpl 2002;8(suppl 1):S28-37.
16. Rosen HR, Martin P. Hepatitis B and C in liver transplant recipient. Semin Liver Dis 2000;20:465-480.
17. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
18. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
19. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358:958-965.
20. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975-982.
21. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Ione O, et al. The long term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-1340.
22. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression with chronic hepatitis C. Lancet 1997;349:825-832.
23. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
24. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852-858.
25. Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, et al. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999;229:824-831; discussion 831-833.
26. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122: 889-896.
27. Everhart JE, Wei Y, Eng H, Charlton MR, Persing DH, Wiesner RH, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999;29:1220-1226.
28. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival after liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
29. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-687.
30. Fukumoto T, Berg T, Ku Y, Bechstein WO, Knoop M, Lemmens HP, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions. Hepatology 1996;24:1351-1354.
31. Gretch DR, Bacchi CE, Corey L, dela Rosa C, Lesniewski RR, Kowdley K, et al. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features. Hepatology 1995;22:1-9.
32. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32:1125-1130.
33. Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Roberts J, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994;106:994-999.
34. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication after liver transplantation. Gastroenterology 1996; 110:167-177.
35. Shiffman ML, Contos MJ, Fisher RA, Mills AS, Luketic VA, Sanyal AJ, et al. Biochemical and histologic evaluation of recurrent hepatitis C after orthotopic liver transplantation. Transplantation 1994;57:526-532.
36. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002;8:S14-18.
37. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
38. Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection. J Hepatol 1998;28: 756-763.
39. Weinstein JS, Poterucha JJ, Zein N, Wiesner RH, Persing DH, Rakela J, et al. Epidemiology and natural history of hepatitis C infections in liver transplantation recipients. J Hepatol 1995; 22:154-159.
40. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118:760-764.
41. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-1457.
42. Doughty AL, Spencer JD, Cossart YE, McCaughan GW, et al. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 1998;4:15-21.
43. Deshpande V, Burd E, Aardema KL, Ma CK, Moonka DK, Brown KA, et al. High levels of hepatitis C virus RNA in native livers correlate with the development of cholestatic hepatitis in liver allografts and a poor outcome. Liver Transpl 2001;7:118-124.
44. Doughty AL, Painter DM, McCaughan GW. Posttransplantation quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis because of hepatitis C virus. J Hepatol 2000;32:126-134.
45. Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M, Ferrell L, et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999;30:1513-1520.
46. Lyra AC, Fan X, Lang DM, Yusim K, Ramrakhiani S, Brunt EM, et al. Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 2002;123:1485-1493.
47. Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, et al. Association of multispecific CD4 (+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999;117:926-932.
48. Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl 2003;9:796-804.
49. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression after transplantation for hepatitis C. Gut 2002;51:248-252.
50. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus, years of transplantation, and donor age on outcome after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-369.
51. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
52. Busuttil RW, Shaked A, Millis JM, Jurim O, Colquhoun SD, Shackleton CR, et al. One thousand liver transplants. The lessons learned. Ann Surg 1994;219:490-497.
53. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002;8(suppl 1):S19-27.
54. McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002;8(suppl 1):S7-13.
55. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group. Transplantation 1998;66: 493-499.
56. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7:442-450.
57. Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs AK. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: A preliminary report. Transplantation 1999;68: 155-157.
58. Jain A, Kashyap R, Kramer D, Dodson F, Hamad I, Starzl TE, et al. Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: Complete report on 350 primary adult liver transplantations. Transplant Proc 2001;33:1342-1344.
59. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132-142.
60. Heffron TG, Smallwood GA, Pillen T, Davis L, Martinez E, Romero R, et al. Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transplant Proc 2002;34:1514-1515.
61. Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998;65: 1044-1046.
62. Fasola C, Netto G, Jennings L, Christensen L, Molmenti E, Sanchez E, et al. Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplant Proc 2002;34:1563.
63. Smallwood G, Davis L, Martinez E, Stieber A, Heffron T. Mycophenolate's influence in the treatment of recurrent hepatitis c after liver transplantation. Transplant Proc 2002;34: 1559.
64. Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001;7:1064-1070.
65. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194-202.
66. Trotter JR, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, Kam I. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001;7:343-351.
67. Wiesner R, Klintmalm G, McDiarmid S, Rapamune Liver Transplant Study Group. Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients [abstract]. Am J Transpl 2002;2(suppl 3):464.
68. Zhu J, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999;117:1198-1204.
69. Shiffman ML, Ferreria-Gonzalez A, Reddy KR, Sterling RK, Luketic VA, Stravitz RT, et al. Comparison of three commercially available assays for HCVRNA utilizing the international unit standard: Implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am J Gastroenterol 2003;98:1159-1166.
70. Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: Possible implications for hepatitis C virus persistence. J Immunol 1999;162:931-938.
71. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest 2000;106:1239-1249.
72. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36(suppl 1):S47-56.
73. Shiffman ML, Brown RB, Olthoff, KM, Everson G, Miller C, Siegler M, Hoofnagle JH. Living donor liver transplantation: Summary of a conference at the National Institutes of Health. Liver Transpl 2002;8:174-188.
74. Brown RS Jr, Russo MW, Lai M, Shiffman ML, Richardson MC, Everhart JE, Hoofnagle JH. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003;348:818-825.
75. Taniguchi M, Wachs M, Bak T, Trotter J, Kugelmas M, Everson G, Kam I. Hepatitis C recurrence in living donor liver transplantation [abstract]. Am J Transpl 2002;2(suppl 2):138.
76. Schiano TD, Branch AD, Chung RT, Kim-Schluger L, Schwartz ME, Bodenheimer HC Jr. HCV RNA levels after liver transplantation: cadaveric versus living donor. Hepatology 2002;36(suppl 1):306A.
77. Shiffman ML, Fisher RA, Stravitz RT, Luketic VA, Sanyal AJ, Mills AS, et al. Histologic analysis or recurrent hepatitis C virus infection after living donor and cadaveric liver transplantation. Am J Transpl 2003;3(suppl 5):203.
78. Peters M. Mechanisms of action of interferons. Semin Liver Dis 1989;9:235-239.
79. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1139-1146.
80. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.
81. Shiffman ML. PEGylated interferons: What role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep 2001;3:30-37.
82. Hadziyannis S, Cheinquer H, Morgan T, Diago M, Jenson D, Sette HJ, et al. Peginterferon alfa-2a (40KD) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining the effect of duration of treatment and ribavirin dose [abstract]. J Hepatol 2002;36(suppl 1):295A.
83. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment naive patients. Semin Liver Dis 1999;19(suppl 1):67-76.
84. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(suppl 1):S237-244.
85. Fattovitch G, Guistina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with interferon. J Hepatol 1994;21:241-243.
86. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26(suppl 1):112S-121S.
87. Izopet J, Rostaing L, Ton-That H, Dubois M, Cazabat M, Charlet JP, et al. Kinetics of HCV viremia in kidney transplant recipients during and after alpha-interferon therapy. Am J Nephrol 1997;17:417-420.
88. Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995;59:1068-1070.
89. Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995;22:1084-1089.
90. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343: 1673-1680.
91. Arnow PM. Infections after orthotopic liver transplantation. HPB Surg 1991;3:221-232.
92. Colquhoun SD, Shaked A, Jurim O, Colonna JO, Rosove MH, Busuttil RW. Reversal of neutropenia with granulocyte colony-stimulating factor without precipitating liver allograft rejection. Transplantation 1993;56:1593-1595.
93. Shiffman ML, Hofmann CM, Sterling RK, Luketic VA, Contos MJ, Sanyal AJ. A randomized, controlled trial to determine if continuing ribavirin as monotherapy in patients who responded to interferon/ribavirin combination therapy will enhance sustained virologic response. J Infect Dis 2001;184: 405-409.
94. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology 2000;31:997-1004.
95. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999;19(supp] 1):17-24.
96. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003;9:741-747.
97. Faure JL, Causse X, Bergeret A, Meyer F, Neidecker J, Paliard P. Cyclosporine induced hemolytic anemia in a liver transplant patient. Transplant Proc 1989;21:2242-2243.
98. Winkler M, Schulze F, Jost U, Ringe B, Pichlmayr R. Anaemia associated with FK 506 immunosuppression. Lancet 1993;341: 1035-1036.
99. Shiffman ML, Di Biseglie A, Lindsay KL, Morishima C, Wright EC, Everson G, et al. Peginterferon alfa-2a for retreatment of patients with chronic HCV who have failed prior treatment with interferon or interferon and ribavirin: Results from the lead-in phase of the hepatitis C long-term treatment against cirrhosis (HALT-C) trial. Gastroenterology 2003 (submitted).
100. Dieterich D, Pockros P, Schiff E, Shiffman M, Sulkowski MS, Wright TL. Epoetin alfa once weekly maintains ribavirin dose in hepatitis C virus-infected patients treated with combination therapy: Interim results of a randomized, double-blind, placebo-controlled study. Hepatology 2002;36:286A.
101. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa treatment of anemic HCV-infected patients allows for maintenance of ribavirin dose, increases hemoglobin levels and improves quality of life vs placebo: A randomized double-blind, multicenter study [abstract]. Gastroenterology 2003;124(suppl 1):A714.
102. Everson GT, Trotter JF, Kugelmas M. Long-term outcomes of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (low dose accelerating-dose regimen). Hepatology 2002;36:297A.
103. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355.
104. Everson G, Trotter J, Kugelmas M. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (Low-Accelerating-Dose Regimen) [abstract]. Hepatology 2002;36:297A.
105. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-1172.
106. Wright HGJ, Van Thiel D. Preliminary experience with alpha 2-b interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992;53:121-124.
107. Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994;20:773-779.
108. Ahmad J, Dodson S, Demetris A, Fung J, Shakil A. Recurrent hepatitis C after liver transplantation: A nonrandomized trial of interferon alfa alone versus interferon alfa plus ribavirin. Liver Transpl 2001;7:870-876.
109. Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27:1403-1407.
110. Coder S, Ganger D, Kaur S, Rosenblate H, Jakate S, Sullivan D, et al. Daily interferon for HCV infection in liver transplant recipients. 2001;71:261-266.
111. Shakil AO, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeevaram H, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002;36:1253-1258.
112. Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001;7:181-190.
113. Brizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26:500-504.
114. Menon K, Poterucha J, El-Amin O, Burgart L, Kremers W, Rosen C. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002;8:623-629.
115. De Vera ME, Smallwood GA, Rosado K, Davis L, Martinez E, Sharma S, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001;71:678-686.
116. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003;124:642-650.
117. Smallwood GA, Davis L, Connor K, Martinez E, Stieber AC, Heffron TG. Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C after liver transplantation. Transpl Proc 2003;35:1476-1477.
118. Khatib A, Arenas J, Carey E, Adyr M, Mulligan D, Ortiz J. Treatment with combination of PEG IFN alfa-2b and ribavirin suppresses viral replication in liver transplantation recipients with recurrent HCV hepatitis [abstract]. Hepatology 2002;36: 182A.
119. Vogel W, Ferenci P, Fontana R, Saab S, LaBrecque D, Pappas S. Peginterferon alfa-2a in liver transplantation recipients with established recurrent hepatitis C: Interim results of an ongoing randomized multicenter trail [abstract]. Hepatology 2002;36: 312A.
120. Bahra M, Neumann UP, Berg T, Neuhaus R, Langrehr JM, Neuhaus P. Pegylated interferon alfa-2b plus ribavirin in patients with hepatitis C reinfection after OLT [abstract]. Am J Transpl 2003;3(suppl 5):432.
121. Ghalib RH, Levine CD, Stribling R, McClelland T, Box TD, Hutson WR, et al. Treatment of recurrent hepatitis C after liver transplantation with pegylated interferon alfa-2b plus ribavirin [abstract]. Gastroenterology 2003;124(suppl 1):A-694.
122. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-1457.
123. Scheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831-838.
124. Vargas V, Charco R, Castells L, Esteban R, Margarit C. Alpha-interferon for acute hepatitis C in liver transplant patients. Transplant Proc 1995;27:1222-1223.
125. Mazzaferro V, Regalia E, Pulvirenti A, Tagger A, Andreola S, Pasquali M, et al. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplant Proc 1997;29:519-521.
126. Reddy RK, Fried MW, Dickson R. Interferon alfa-2b and ribavirin vs. placebo as early treatment in patients transplanted for hepatitis C related end-stage liver disease: Results of a multicenter, randomized trial [abstract]. Gastroenterology 2002; 122:A-632.
127. The METAVIR cooperative group. Inter- and intra-variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1996;24:778-789.
128. Ishak K, Baptista A, Bianchi L, Callea F, DeGroote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
129. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, et al. Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-785.
130. Nair S, Khan S, Loss G, Eason J, Blazek J, Lipscomb J, Mason A. Treatment of recurrent hepatitis C in liver transplant recipients: Is there any histologic benefit? Liver Transpl 2003;9:354-359.
131. Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Ashworth A, et al. Histologic evaluation of interferon/ribavirin therapy in liver transplant recipients with recurrent hepatitis C: Evidence or rejection despite virologic response [abstract]. Am J Transpl 2003;3(suppl 5):294.
132. Gatof D, Trotter JF, Everson GT. Severe ductopenic rejection associated with clearance of hepatitis C virus on interferon therapy after liver transplantation [abstract]. Hepatology 2002; 36:291A.
133. Ghobrial RM. Retransplantation for recurrent HCV. Liver Transpl 2002;8(suppl 1):S38-S44.
134. Sheiner PA, Schluger LK, Emre S, Thung SN, Lau JY, Guy SR, et al. Retransplantation for hepatitis C. Liver Transpl Surg 1997;3:130-136.
135. Markmann JF, Markowitz JS, Yersiz H, Morrissey M, Farmer DG, Farmer DA, et al. Long term survival after retransplantation of the liver. Ann Surg 1997;226:408-420.
136. Doyle HR, Morelli F, McMichael J, Doria C, Aldrighetti L, Starzl TE, Marino IR. Hepatitic retransplantation. An analysis of risk factors associated with outcome. Transplantation 1996; 61:1499-1505.
137. Rosen H, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998;66:1612-1616.
138. Alter MJ. Epidemiology of hepatitis C in the west. Semin Liver Dis 1995;15:5-14.
139. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-782.
140. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
141. Jacobsen IM, Ahmed F, Russo MW, Brown RS, Lebovics E, Min A, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: Final results. Gastroenterology 2003;124(suppl 1):A-714.
142. Shiffman ML. Management of interferon therapy nonresponders. Clin Liver Dis 2001;5:1025-1043.
143. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002;36(suppl 1):S128-S134.